摘要
目的:观察抗Endoglin mAb对胰腺癌生长的影响.方法:建立裸小鼠人类胰腺癌细胞动物模型,将44只裸小鼠随机分为抗体组和生理盐水组,抗体组在接种胰腺癌细胞的同时,经腹腔注射抗Endoglin mAb;生理盐水组在接种胰腺癌细胞的同时,经腹腔注射生理盐水,计算肿瘤体积和抑瘤率,并做组织病理学检查.结果:抗体组小鼠一般情况明显比注射生理盐水组好;抗Endoglin mAb可抑制人类胰腺癌细胞株PC-3的生长,抑瘤率为67.13%,抗体组与生理盐水组比较肿瘤明显受抑制(P<0.05).结论:抗Endoglin mAb对人类胰腺癌细胞株PC-3的生长有明显的抑制作用,有希望作为胰腺癌的生物基因治疗方法.
AIM： To observe the inhibitory effect of anti-Endoglin monoclonal antibody on tumor growth of pancreatic carcinoma. METHODS： We established an animal model of human pancreatic carcinoma in nude mice and the tumor inhibiting activity of anti-Endoglin monoclonal antibody was tested. Forty-four nude mice of human pancreatic carcinoma were randomly assigned to 2 groups： antibody group in which the mice were treated with monoclonal antibody and saline group in which the mice were given normal saline. The tumor volume and the tumor growth inhibition rate were calculated and the tumor was histopathlogically measured. RESULTS： Compared with that in control group, the general state of the mice in antibody group was better and the growth of human pancreatic carcinoma cell PC-3 in antibody group was dramatically inhibited. Compared with that in normal saline group, the growth of the tumor was significantly reduced in size in the mice treated with anti-Endoglin monoclonal antibody, with an inhibition rate of 67. 13%. CONCLUSION： The anti-Endoglin monoclonal antibody has a significant inhibitory effect on mouse pancreatic carcinoma cell PC-3, t indicating that the anti-Endoglin monoclonal antibody is a promising biological treatment for pancreatic carcinoma.
出处
《第四军医大学学报》
北大核心
2009年第6期520-522,共3页
Journal of the Fourth Military Medical University
基金
广东省医学科研课题(A2003563)
